SHINE Signs $125M Term Sheet

2017-08-01T08:46:46+00:00

SHINE Medical Technologies, Inc. (SHINE) announced today that it executed a term sheet providing for up to $125 million of debt and equity financing with Deerfield Management Company, L.P. (Deerfield), a New York headquartered healthcare investment firm. SHINE plans to build a new manufacturing plant in Wisconsin to produce more than a quarter of world supply of the most commonly-used isotope in nuclear medicine, molybdenum-99 (moly-99).

SHINE Signs $125M Term Sheet 2017-08-01T08:46:46+00:00

SHINE Medical and Phoenix Nuclear Achieve Key Technical Milestone

2017-07-31T19:27:03+00:00

SHINE Medical Technologies and Phoenix Nuclear Labs (PNL) announced today that they successfully operated their second-generation neutron driver prototype for 24 consecutive hours with 99% uptime. Completion of this milestone is an important demonstration of the reliability and robustness of the PNL neutron driver, which is a key enabling technology for SHINE’s isotope production facility.

SHINE Medical and Phoenix Nuclear Achieve Key Technical Milestone 2017-07-31T19:27:03+00:00

SHINE to Hold Information Session

2017-08-01T08:50:16+00:00

SHINE Medical Technologies, Inc. (SHINE Medical), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes and cancer treatment elements, announced today that it will present an update on its progress in the development and planning for its Janesville medical isotope facility on Wednesday, June 18th at the Holiday Inn Express, 3100 Wellington Place in Janesville.

SHINE to Hold Information Session 2017-08-01T08:50:16+00:00

James L. Connaughton Joins SHINE

2017-08-01T08:50:34+00:00

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, announced today that James L. Connaughton has agreed to serve as a strategic advisor to management as SHINE continues its efforts to bring molybdenum-99 (moly-99) to market.

James L. Connaughton Joins SHINE 2017-08-01T08:50:34+00:00

SHINE to Supply Mo-99 to GE Healthcare

2017-08-01T08:50:48+00:00

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin‐based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, announced today that it has entered into a strategic long‐term supply agreement with GE Healthcare, a division of the General Electric Company, for supply of molybdenum‐99 (moly‐99).

SHINE to Supply Mo-99 to GE Healthcare 2017-08-01T08:50:48+00:00

SHINE Construction Permit Application Accepted by NRC

2017-09-18T13:31:20+00:00

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes and cancer treatment elements, announced today that the Nuclear Regulatory Commission (NRC) has accepted for review the second half of SHINE’s construction permit application to build a medical isotope production plant near Janesville, WI.

SHINE Construction Permit Application Accepted by NRC 2017-09-18T13:31:20+00:00

NRC Dockets SHINE Construction Permit Application

2017-09-18T13:30:34+00:00

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has received notice that the Nuclear Regulatory Commission (NRC) has accepted the first part of its Construction Permit application for review and docketing. This is the first formal step by the NRC in the construction permitting process for the SHINE medical isotope facility in Janesville, Wisconsin.

NRC Dockets SHINE Construction Permit Application 2017-09-18T13:30:34+00:00

SHINE to Hold Information Session

2017-09-25T09:34:23+00:00

SHINE Medical Technologies, Inc. (SHINE Medical), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes and cancer treatment elements, announced today that it will present an update on its progress in the development and planning for its Janesville medical isotope facility on Thursday, June 13th at the Holiday Inn Express, 3100 Wellington Place in Janesville.

SHINE to Hold Information Session 2017-09-25T09:34:23+00:00

SHINE Files 2nd Part of NRC Construction Permit Application

2017-08-01T08:53:08+00:00

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has submitted the remaining chapters of its Construction Permit application to the Nuclear Regulatory Commission (NRC).

SHINE Files 2nd Part of NRC Construction Permit Application 2017-08-01T08:53:08+00:00